Fernanda Andrade
Autonomous University of Barcelona
47 Papers
242 Citations
Fernanda Andrade is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Drug delivery & Cancer stem cell. The author has an hindex of 20, co-authored 47 publications. Previous affiliations of Fernanda Andrade include Carlos III Health Institute & University of Barcelona.
Chat about Author
Papers
Lipid-based nanovesicles for nanomedicine.
Natascia Grimaldi,Fernanda Andrade,N. Segovia,Lidia Ferrer-Tasies,Santiago Sala,Jaume Veciana,Nora Ventosa +6 more
TL;DR: This new generation of nanovesicles can represent a paradigm shift in nanomedicine: they may complement liposomes, showing their advantages and overcoming most of their drawbacks, and extensively review the current approaches exploited for L-NV production.
Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs
TL;DR: The results suggest that Caco-2/HT29/Raji B triple co-culture normal oriented cellular model may be reliable to obtain a more physiological, functional, and reproducible in vitro model of the intestinal barrier to study protein absorption, both in solution and when delivered by nanocarriers.
259
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
Fernanda Andrade,Diana Rafael,Mafalda Videira,Domingos Ferreira,Alejandro Sosnik,Alejandro Sosnik,Alejandro Sosnik,Bruno Sarmento +7 more
TL;DR: Nanotechnology-based drug delivery systems (nano-DDS) emerged as a promising approach to circumvent the limitations of conventional formulations and to treat drug resistance, opening the hypothesis for new developments in this area.
225
Models to predict intestinal absorption of therapeutic peptides and proteins.
TL;DR: In silico, in vitro, in situ, ex vivo and in vivo methods used to predict human intestinal absorption are described, giving a special attention to the intestinal absorption of therapeutic peptides and proteins.
103
Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.
TL;DR: Results pose a strong argument that the developed nanocarrier can be explored as a promising carrier for safer and more efficient management of tuberculosis by exploiting the pulmonary route of administration.